FindTrial
Sign In

18F-DCFPyL Injection

DRUG6 trials

Sponsors

Progenics Pharmaceuticals, Inc., Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Conditions

Malignant TumorsMetastatic Prostate CancerProstate CancerSchwannomas

Phase 1

Evaluation of 18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer.
CompletedNCT03497377
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsMetastatic Prostate Cancer
Start: 2016-05-16End: 2020-04-30Updated: 2020-05-07
Targeted Imaging of Glutamate Carboxypeptidase II With DCFPyL-PET
CompletedNCT03542773
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsMalignant Tumors, Schwannomas
Start: 2015-02-06End: 2022-05-01Updated: 2023-01-11
Test-Retest Reproducibility of 18F-DCFPyL PET/CT in the Evaluation of Patients With Metastatic Prostate Cancer
CompletedNCT03793543
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsProstate Cancer
Start: 2019-03-27End: 2021-10-15Updated: 2021-12-15

Phase 2

Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer
CompletedNCT02981368
Progenics Pharmaceuticals, Inc.Prostate Cancer
Start: 2016-11-30End: 2018-07-31Updated: 2021-08-09
Study of PSMA-targeted 18F-DCFPyL PET/CT for the Detection of Clinically Significant Prostate Cancer
Active, not recruitingNCT03471650
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsProstate Cancer
Start: 2018-03-29End: 2028-03-07Target: 150Updated: 2026-03-30
Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer
WithdrawnNCT03800784
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsProstate Cancer
Start: 2019-10-01End: 2021-10-21Updated: 2021-12-15

Related Papers

Impact of Concomitant Hormone Therapy on the Diagnostic Performance of <sup>18</sup>F‐Piflufolastat PET/CT in Prostate Cancer Patients: A Sub‐Group Analysis of OSPREY Cohort B
The Prostate2025-05-04
Test–retest repeatability of organ uptake on PSMA‐targeted <sup>18</sup>F‐DCFPyL PET/CT in patients with prostate cancer
The Prostate2023-05-212 citations
Changes in planned disease management after piflufolastat F<sup>18</sup> PET/CT in men with biochemically recurrent prostate cancer and low PSA levels: A secondary analysis of results from the CONDOR study.
Journal of Clinical Oncology2023-02-201 citations
Piflufolastat F 18-PET/CT in patients with prostate cancer: An analysis of OSPREY (cohorts A and B) standardized uptake value (SUV) results stratified by PSA and Gleason score.
Journal of Clinical Oncology2022-06-011 citations
Piflufolastat F 18-PET/CT in prostate cancer patients: An analysis of OSPREY (Cohorts A and B) standardized uptake value (SUV) results stratified by PSA and gleason score.
Journal of Clinical Oncology2022-02-16
High SUVs Have More Robust Repeatability in Patients with Metastatic Prostate Cancer: Results from a Prospective Test-Retest Cohort Imaged with <sup>18</sup>F-DCFPyL
Molecular Imaging2022-01-0111 citations
Updated Analysis of 18F-DCFPyL PET/CT Imaging for Prostate Cancer
Oncology Times2021-11-19
MP11-11 CHANGES TO INITIAL RISK ASSESSMENT AND INTENDED PATIENT MANAGEMENT IN HIGH-RISK PROSTATE CANCER: AN EXPLORATORY ANALYSIS OF COHORT A FROM THE OSPREY TRIAL
The Journal of Urology2021-08-04
A prospective phase 2/3 study of PSMA-targeted <sup>18</sup>F-DCFPyL-PET/CT in patients (pts) with prostate cancer (PCa) (OSPREY): A sub-analysis of disease staging changes in PCa pts with recurrence or metastases on conventional imaging.
Journal of Clinical Oncology2021-05-20
A prospective phase II/III study of PSMA-targeted 18F-DCFPyL-PET/CT in patients (pts) with prostate cancer (PCa) (OSPREY): A subanalysis of disease staging changes in PCa pts with recurrence or metastases on conventional imaging.
Journal of Clinical Oncology2021-02-202 citations
PD38-05 CLINICAL UTILITY OF PREOPERATIVE PSMA-TARGETED <sup>18</sup> F-DCFPYL PET/CT IN MEN WITH HIGH-RISK PROSTATE CANCER: DIAGNOSTIC PERFORMANCE COMPARISONS WITH PELVIC CT OR MRI IN THE OSPREY PROSPECTIVE, MULTI-CENTER TRIAL
The Journal of Urology2020-04-011 citations
A prospective phase II/III multicenter study of PSMA-targeted 18F-DCFPyL PET/CT imaging in patients with prostate cancer (OSPREY): A sub-analysis of regional and distant metastases detection rates at initial staging by 18F-DCFPyL PET/CT.
Journal of Clinical Oncology2020-02-1912 citations
Diagnostic performance of <sup>18</sup>F-DCFPyL in the OSPREY Trial: A prospective phase 2/3 multicenter study of <sup>18</sup>F-DCFPyL PET/CT imaging in patients (Pts) with known or suspected metastatic prostate cancer (mPC).
Journal of Clinical Oncology2019-05-203 citations
PD60-10 A PROSPECTIVE PHASE 2/3 MULTI-CENTER STUDY OF <sup>18</sup> F-DCFPYL PET/CT IMAGING IN PATIENTS WITH PROSTATE CANCER – EXAMINATION OF DIAGNOSTIC ACCURACY (OSPREY)
The Journal of Urology2019-04-01
A prospective phase 2/3 multicenter study of <sup>18</sup>F-DCFPyL PET/CT imaging in patients with prostate cancer: Examination of diagnostic accuracy (OSPREY).
Journal of Clinical Oncology2018-05-205 citations